Chaudhary Uzair B, Rashid Mohammad H, Onitilo Adedayo A, Bissada Nabil K
Department of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72202, USA.
Can J Urol. 2005 Jun;12(3):2666-76.
Prostate cancer is a heterogeneous disease and clinical outcomes vary considerably after failure of primary androgen ablation. With the development of new therapeutics the management of patients with androgen independent prostate cancer has changed considerably over the last few years. Multiple secondary hormonal manipulations are available and may lead to prolonged periods of clinical response. These maneuvers include the use of oral antiandrogens, antiandrogen withdrawal, ketoconazole, aminoglutethimide, corticosteroids and use of estrogenic compounds. This article reviews the clinical activity of these agents in management of patients with advanced prostate cancer.
前列腺癌是一种异质性疾病,初次雄激素剥夺治疗失败后的临床结局差异很大。随着新疗法的发展,过去几年中雄激素非依赖性前列腺癌患者的管理发生了很大变化。有多种二线激素治疗方法可供选择,可能会带来较长时间的临床缓解。这些方法包括使用口服抗雄激素药物、抗雄激素撤药、酮康唑、氨鲁米特、皮质类固醇以及使用雌激素类化合物。本文综述了这些药物在晚期前列腺癌患者管理中的临床活性。